Intelligent Bio Solutions Stock Today
| INBS Stock | USD 2.16 0.07 3.35% |
PerformanceGood
| Odds Of DistressQuite High
|
Intelligent Bio is selling for under 2.16 as of the 23rd of March 2025; that is 3.35% up since the beginning of the trading day. The stock's lowest day price was 2.05. Intelligent Bio has more than 66 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 23rd of December 2020 | Category Healthcare | Classification Health Care |
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd. Intelligent Bio operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 4.39 M outstanding shares of which 387.1 K shares are currently shorted by private and institutional investors with about 1.25 trading days to cover. More on Intelligent Bio Solutions
Moving together with Intelligent Stock
Moving against Intelligent Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Intelligent Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Harry Simeonidis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intelligent Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Intelligent Bio's financial leverage. It provides some insight into what part of Intelligent Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Intelligent Bio Solutions (INBS) is traded on NASDAQ Exchange in USA. It is located in 135 West, 41ST Street, New York, NY, United States, 10036 and employs 50 people. Intelligent Bio is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.14 M. Intelligent Bio Solutions conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 4.39 M outstanding shares of which 387.1 K shares are currently shorted by private and institutional investors with about 1.25 trading days to cover.
Intelligent Bio Solutions currently holds about 8.28 M in cash with (9.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.56.
Check Intelligent Bio Probability Of Bankruptcy
Ownership AllocationIntelligent Bio retains 3.01 (percent) of its outstanding shares held by insiders and 14.38 (percent) owned by outside corporations.
Check Intelligent Ownership Details
Intelligent Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 26.6 K | |
| Alyeska Investment Group, L.p. | 2024-12-31 | 0.0 | |
| Vanguard Group Inc | 2024-12-31 | 15.5 K | |
| Two Sigma Securities, Llc | 2024-12-31 | 15.4 K | |
| Ground Swell Capital, Llc | 2024-12-31 | 10.4 K | |
| Tower Research Capital Llc | 2024-12-31 | 5.8 K | |
| Ubs Group Ag | 2024-12-31 | 2.9 K | |
| Sbi Securities Co Ltd | 2024-12-31 | 201 | |
| Royal Bank Of Canada | 2024-09-30 | 55.0 | |
| Bank Of America Corp | 2024-12-31 | 36.0 | |
| Adar1 Capital Management Llc | 2024-12-31 | 0.0 |
Intelligent Bio Historical Income Statement
Intelligent Stock Against Markets
Intelligent Bio Corporate Management
| BBus CA | Chief Officer | Profile | |
| Alex Arzeno | VP Relations | Profile | |
| Victoria Gavrilenko | Operations Manager | Profile | |
| Anna Turkington | Vice Marketing | Profile | |
| Callistus Sequeira | Vice Operations | Profile | |
| Doug Heath | Vice Sales | Profile |
Additional Tools for Intelligent Stock Analysis
When running Intelligent Bio's price analysis, check to measure Intelligent Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intelligent Bio is operating at the current time. Most of Intelligent Bio's value examination focuses on studying past and present price action to predict the probability of Intelligent Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intelligent Bio's price. Additionally, you may evaluate how the addition of Intelligent Bio to your portfolios can decrease your overall portfolio volatility.